Search Browse Earnings

Lexaria Bioscience Corp.

Nasdaq:LEXX

Pharmaceutical Preparations·KELOWNA, A1

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

CEO

Christopher Richard

Revenue

$226,208

-11.4% YoY

FY 2024

Adj. EBITDA

-$5.7M

-2524.5% margin

FY 2025

Net Income

-$5.8M

-2562.0% margin

FY 2025

EPS (Diluted)

-$0.47

FY 2025

Stock Price

$0.72

+0.1%

2026-03-11

52W Range

$0.46 – $1.90

P/E Ratio

-1.5x

Market Cap

$17.9M

Cash

$10.9M

FY 2022

Total Debt

—

Net Cash

$10.9M

FY 2024

Enterprise Value

$7.0M

Debt / EBITDA

1.9x

FY 2024

EV / EBITDA

-1.2x

Employees

—